| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yini Liao, Brian S Muntea. KCTD1 regulation of Adenylyl cyclase type 5 adjusts striatal cAMP signaling. Proceedings of the National Academy of Sciences of the United States of America. vol 121. issue 43. 2024-10-16. PMID:39413138. |
dopamine transfers information to striatal neurons, and disrupted neurotransmission leads to motor deficits observed in movement disorders. |
2024-10-16 |
2024-10-19 |
mouse |
| Huifang Wu, Minghao Yan, Tong Wu, Xiaodong Ha. MC-LR disrupts dopamine synthesis in the substantia nigra of midbrain by enhancing the chaperone-mediated autophagy pathway through direct binding to ERK2. Journal of hazardous materials. vol 480. 2024-10-16. PMID:39413523. |
the reduction in dopamine levels is a key factor contributing to movement disorders in humans with pd. |
2024-10-16 |
2024-10-19 |
mouse |
| Jinming Liu, Zhongqing Ji, Qisheng He, Huanhuan Chen, Xiaojing Xu, Qiuhao Mei, Ya'nan Hu, Huanxiang Zhan. Direct conversion of human umbilical cord mesenchymal stem cells into dopaminergic neurons for Parkinson's disease treatment. Neurobiology of disease. 2024-09-29. PMID:39343249. |
furthermore, cins treatment significantly increased the number of tyrosine hydroxylase-positive cells and the concentration of dopamine in the striatum, effectively ameliorating movement disorders in pd mice. |
2024-09-29 |
2024-10-02 |
mouse |
| Ranran Lu, Xu Zhou, Lijie Zhang, Mengdie Hao, Xinling Yan. Nrf2 Deficiency Exacerbates Parkinson's Disease by Aggravating NLRP3 Inflammasome Activation in MPTP-Induced Mouse Models and LPS-Induced BV2 Cells. Journal of inflammation research. vol 17. 2024-09-16. PMID:39281779. |
parkinson's disease (pd) is a movement disorder characterized by the progressive loss of dopamine neurons. |
2024-09-16 |
2024-09-19 |
mouse |
| Ahmed Bouhouche, Leila Tamaoui, Nazha Birou. The Pan African medical journal. vol 47. 2024-07-08. PMID:38974698. |
dopa-responsive dystonia (drd) is a hereditary movement disorder due to a selective nigrostriatal dopamine deficiency. |
2024-07-08 |
2024-07-11 |
Not clear |
| Hannah Holden, Shruti Venkatesh, Carla Budrow, Sareen Nezaria, Michael Coyle, Ashley Centner, Natalie Lipari, Grace McManus, Christopher Bisho. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease. Physiology & behavior. vol 281. 2024-05-25. PMID:38723388. |
parkinson's disease (pd) is a neurodegenerative movement disorder characterized by dopamine (da) cell loss in the substantia nigra pars compacta (snc). |
2024-05-25 |
2024-05-27 |
rat |
| Ratna Dini Haryuni, Takamasa Nukui, Jin-Lan Piao, Takashi Shirakura, Chieko Matsui, Tomoyuki Sugimoto, Kousuke Baba, Shunya Nakane, Yuji Nakatsuj. Elevated Serum Xanthine Oxidase and Its Correlation with Antioxidant Status in Patients with Parkinson's Disease. Biomolecules. vol 14. issue 4. 2024-04-27. PMID:38672506. |
parkinson's disease (pd) is a neurodegenerative movement disorder associated with a loss of dopamine neurons in the substantia nigra. |
2024-04-27 |
2024-04-29 |
Not clear |
| Jerzy K Kulski, Shingo Suzuki, Takashi Shiina, Abigail L Pfaff, Sulev Kõk. Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson's disease. Frontiers in immunology. vol 15. 2024-04-09. PMID:38590523. |
parkinson's disease (pd) is a neurodegenerative and polygenic disorder characterised by the progressive loss of neural dopamine and onset of movement disorders. |
2024-04-09 |
2024-04-11 |
human |
| Roongroj Bhidayasiri, Onanong Phokaewvarangkul, Hui-Fang Shang, Thien Thien Lim, Jin Whan Cho, Pramod Kumar Pal, Hirohisa Watanab. Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway. Frontiers in neurology. vol 15. 2024-02-29. PMID:38419696. |
tardive dyskinesia (td) is a movement disorder that can arise as a side effect of treatment with dopamine receptor-blocking agents (drbas), including antipsychotic drugs (apds) used to manage psychotic illnesses. |
2024-02-29 |
2024-03-02 |
Not clear |
| Suzita Mohd Noor, Chee Ern David Wong, Pooi-Fong Wong, Anwar Norazi. Generation of glial cell-derived neurotrophic factor (gdnf) morphants in zebrafish larvae by cerebroventricular microinjection of vivo morpholino. Methods in cell biology. vol 181. 2024-02-01. PMID:38302238. |
deficiency of dopamine due to advanced age and accumulative dopaminergic neuron defects can lead to movement disorders such as parkinson's disease. |
2024-02-01 |
2024-02-04 |
human |
| Louisa A Christie, Nicola L Brice, Anna Rowland, Louise Dickson, Rishi Anand, Martin Teall, Kevin J Doyle, Lakshminarayana Narayana, Christine Mitchell, Jenna R M Harvey, Victoria Mulligan, Lee A Dawson, Stephanie J Cragg, Mark Carlton, Roland W Bürl. Discovery of Journal of medicinal chemistry. 2023-08-31. PMID:37651656. |
this subunit modulates dopamine neurotransmission and may have therapeutic potential in movement disorders. |
2023-08-31 |
2023-09-07 |
Not clear |
| Gabriella Tandra, Amy Yoone, Rhea Mathew, Minzhi Wang, Chadwick M Hales, Cassie S Mitchel. Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease. International journal of molecular sciences. vol 24. issue 15. 2023-08-12. PMID:37569714. |
parkinson's disease (pd) is a movement disorder caused by a dopamine deficit in the brain. |
2023-08-12 |
2023-08-16 |
Not clear |
| Leslie Citrome, Jonathan M Meye. Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management. The Journal of clinical psychiatry. vol 84. issue 4. 2023-08-09. PMID:37555680. |
for decades, treatment for schizophrenia has focused on antipsychotics (aps) that reduce excess dopamine signaling to the associative striatum, which also blocks dopamine signaling in the dorsal striatum, creating movement disorders. |
2023-08-09 |
2023-08-16 |
Not clear |
| Z A Zalyalov. [Tardive dyskinesia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 123. issue 7. 2023-07-25. PMID:37490662. |
tardive dyskinesia (td) is a delayed, often irreversible iatrogenic movement disorder caused by long-term use of that dopamine receptors blocking drugs. |
2023-07-25 |
2023-08-14 |
Not clear |
| Robert B Kargb. Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Parkinson's Disease and Amyotrophic Lateral Sclerosis. ACS medicinal chemistry letters. vol 14. issue 7. 2023-07-19. PMID:37465304. |
parkinson's disease (pd) is a neurodegenerative movement disorder characterized by symptoms like resting tremor, rigidity, bradykinesia, and postural instability, mainly due to dopamine depletion and degeneration of dopaminergic neurons. |
2023-07-19 |
2023-08-14 |
Not clear |
| Joanne Ng, Serena Barral, Simon N Waddington, Manju A Kuria. Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches. Cells. vol 12. issue 13. 2023-07-14. PMID:37443770. |
infantile parkinsonism-dystonia due to dopamine transporter deficiency syndrome (dtds) is an ultrarare childhood movement disorder caused by biallelic loss-of-function mutations in the |
2023-07-14 |
2023-08-14 |
Not clear |
| Lenka Hasíková, Jakub Závada, Tereza Serranová, Petr Kozlík, Květa Kalíková, Lenka Kotačková, Jiří Trnka, David Zogala, Karel Šonka, Evžen Růžička, Petr Duše. Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson's disease. NPJ Parkinson's disease. vol 9. issue 1. 2023-04-12. PMID:37045835. |
pd patients were examined using movement disorder society-unified parkinson's disease rating scale (mds-updrs), montreal cognitive assessment (moca), scales for outcomes in parkinson disease-autonomic (scopa-aut), the university of pennsylvania smell identification test (upsit), one-night video-polysomnography, and dopamine transporter single-photon emission computed tomography (dat-spect). |
2023-04-12 |
2023-08-14 |
Not clear |
| Kaitlyn M Roman, Maria A Briscione, Yuping Donsante, Jordan Ingram, Xueliang Fan, Douglas Bernhard, Simone A Campbell, Anthony M Downs, David Gutman, Tejas A Sardar, Sofia Q Bonno, Diane J Sutcliffe, H A Jinnah, Ellen J Hes. Striatal subregion-selective dysregulated dopamine receptor-mediated intracellular signaling in a model of DOPA-responsive dystonia. Neuroscience. 2023-03-05. PMID:36871883. |
although adaptations in striatal dopamine receptor-mediated intracellular signaling have been studied extensively in models of parkinson's disease, another movement disorders associated with dopamine deficiency, little is known about dopaminergic adaptations in dystonia. |
2023-03-05 |
2023-08-14 |
mouse |
| Yu-Hsuan Chen, Yi-Ying Kuo, Yi-Qian You, Ya-Tin Lin, Pei-Chun Che. Endonuclease VIII-like 1 deficiency potentiates nigrostriatal dopaminergic neuron degeneration in a male mouse model of Parkinson's disease. Journal of neurochemistry. 2023-02-25. PMID:36840377. |
parkinson's disease (pd) is a common movement disorder caused by a characteristic loss of dopaminergic neurons in the substantia nigra (sn) and degeneration of dopamine terminals in the dorsal striatum. |
2023-02-25 |
2023-08-14 |
mouse |
| Katsunori Kitan. The network configuration in Parkinsonian state compensates network activity change caused by loss of dopamine. Physiological reports. vol 11. issue 4. 2023-02-21. PMID:36802196. |
parkinson's disease is a movement disorder caused by dopamine depletion in the basal ganglia. |
2023-02-21 |
2023-08-14 |
Not clear |